Peptide modifications for structure, stability and detection
Terminal caps, cyclization, stapling, PTMs, fluorescent and affinity tags, PEG/lipid appendages and unnatural backbones—installed during SPPS or in solution after the chain is built. Each class changes synthesis time, purification and how the product should be specified on the COA.
50+
modification types (typical catalog)
+2–10 d
lead time vs linear (indicative)
Site-specific
single-position installs
Ortho
protected Cys pairs (common)
LC-MS
modification confirmation
How modifications are introduced
Most tags and caps are incorporated as Fmoc-protected building blocks or orthogonally deprotected side chains on resin. Head-to-tail and side-chain-to-side-chain cyclizations often combine on-resin lactam formation with solution-phase disulfide or thioether closing.
Quote with the exact position (one-letter index), stereochemistry and any linker length. Ambiguous placement is a common source of out-of-spec analytics on fluorescent and PEGylated peptides.
Modification catalog (by class)
Lead-time impact is indicative versus a standard linear peptide of similar length at the same purity tier. Figures are indicative industry-typical values. Lot- and project-specific data appear on the quotation and certificate of analysis.
N-terminal (+0–2 d typical)
- Acetyl, formyl, fatty acid (C12–C18), biotin-PEG
- FAM / 5-TAMRA / Cy dye on N-terminus or side chain
- Myristoyl, palmitoyl for membrane association studies
C-terminal (+0–2 d)
- Amidation, ethylamide, rescue tags
- C-terminal lysine or cysteine handles for conjugation
Cyclization (+3–7 d)
- Head-to-tail amide lactam
- Disulfide bridges (1–3 pairs)
- Side-chain lactam (Asp/Lys, Glu/Cys templates)
- CuAAC or click macrocycles (where compatible)
Stapling (+5–10 d)
- i, i+4 and i, i+7 hydrocarbon stapled helices (R8 or S5 crosslinkers)
- Thioether staples after ring-closing metathesis partners
PTM mimics (+2–5 d)
- Phospho-Ser/Thr/Tyr (protected or global deprotection strategy)
- Acetyl-Lys, methyl-Arg/Lys analogs
- Citulline and nitro-Tyr for immunology antigens
Labels & quenchers (+2–4 d)
- FAM, TAMRA, Cy3/Cy5, Alexafluor analogs
- Dabcyl / QXL quencher pairs for FRET probes
- DOTA/NOTA chelator on Lys or Cys
Polymers & lipids (+3–6 d)
- Linear PEG (5–40 kDa) on Cys or Lys
- 2–4× lipid chain conjugation for half-life studies
- Cholesterol or tocopherol appendages
Conjugates (+5–14 d)
- Maleimide–protein coupling (peptide supplied activated)
- KLH / OVA carrier peptides for immunization
- Drug-linker handles (non-GMP discovery quantities)
Unnatural backbones (+4–10 d)
- D-amino acids at defined positions
- N-methyl amino acids, β-homo and Aib scans
- ε-methyl-Lys, ornithine, NorLeu replacements
Which modification for your goal
| Goal | Common approach | Specify on COA |
|---|---|---|
| Protease stability | N-acetyl, C-amide, D-residue scan, staple | Terminal caps, site of unnatural AA |
| Receptor binding (helical) | Hydrocarbon staple, lactam constraint | Staple positions, cis/trans olefin where relevant |
| Immunoassay detection | Biotin or digoxigenin, spacer length | Label position, spacer atoms |
| Cell uptake imaging | TAMRA, Cy5, cell-penetrating sequence | Dye equivalence, purity of dye building block |
| PK / half-life extension | PEGylation, lipidation, albumin-binding tag | PEG size, number of lipids |
| Radiometal chelation | DOTA on Lys; optional disulfide cyclization | Metal-free chelator content, identity |
| Vaccine antigen | Phospho-peptide, KLH conjugation | Phospho site, carrier ratio (indicative) |
Figures are indicative industry-typical values. Lot- and project-specific data appear on the quotation and certificate of analysis.
Analytics for modified peptides
Identity
LC-MS (expected Δ mass)
HRMS for complex PEG or lipid
Purity
RP-HPLC
Fluorescent: monitor wavelength matched to dye
Cyclization
MS confirms closed form
Optional disulfide mapping for multi-Cys
Phosphorylation
LC-MS, optional P-31 NMR
Labile phospho may need gentle handling
PEG
SEC or MALDI alongside RP-HPLC
Broad peak is expected for high MW PEG
Figures are indicative industry-typical values. Lot- and project-specific data appear on the quotation and certificate of analysis.
Cyclization workflow (indicative)
Orthogonal protection design
Route disulfides, lactams and staples without premature deprotection during Fmoc cycles.
Linear assembly
SPPS with modified and standard amino acids; critical couplings may be doubled.
Global deprotection / cleavage
TFA cleavage or hydrazide-assisted chemistries for thioether staples.
Ring closure
Air oxidation, DMSO-mediated disulfide, or on-resin lactam with coupling agents.
Purification and release
RP-HPLC to separate open-chain impurities; MS confirms cyclic mass.
Deliverables
- Lyophilized modified peptide at agreed purity
- COA with modification position called out in the description
- MS data showing expected adduct or closed mass
- Optional: chiral confirmation for critical D-residue positions (quoted)
- Material safety and handling notes for dyes or lipids
Frequently asked questions
Often yes, but order of operations matters. Staple first, then PEG on an orthogonal handle is a common sequence. Combined complexity is quoted after route review.
Related
Custom Peptide Synthesis
Solid-phase and solution synthesis of linear and modified peptides for discovery, assay development and lead optimization. Scale, purity tier and QC depth are matched to how the material will be used—not every program needs the same finishing step.
View detailsDiagnostic & Device Peptides
Highly controlled peptides for immunoassays, biosensors, calibration curves and device coatings—where lot-to-lot consistency, label integrity and low host-interference matter more than gram-scale bulk.
View detailsCosmetic Peptides
Signal peptides, carrier peptides and synthetic neuropeptide mimics for skin and hair care, supplied at cosmetic raw material purity with INCI-aligned naming and documentation suitable for PIF and safety assessments—not pharmaceutical release unless separately contracted.
View detailsAmino Acid Derivatives
Fmoc and Boc protected amino acids, pseudoproline dipeptides, phosphorylated and unnatural derivatives, and pre-activated forms for SPPS. Lot-enantiomeric purity at the monomer propagates into the final peptide—especially on long sequences.
View detailsReady to specify this for your program?
Share sequence, scale and documentation needs. We reply with indicative specs and a project-specific quotation.